SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Leerink Partners维持Pyxis Oncology(PYXS.US)买入评级
Leerink Partners analyst Jeffrey La Rosa maintains $Pyxis Oncology(PYXS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -6.6%
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Pyxis Oncology Analyst Ratings
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Swayampakula Ramakanth maintains $Pyxis Oncology(PYXS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
LifeSci Capital analyst Sam Slutsky maintains $Pyxis Oncology(PYXS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.8% and a total average return of 3.9% over
Pyxis Oncology GAAP EPS of -$0.29
Express News | Pyxis Oncology Inc: Expected Cash Runway Into 2H 2026
Pyxis Oncology | 10-Q: Q2 2024 Earnings Report
Express News | Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Express News | Pyxis Oncology Q2 Net Income USD -17.301 Million Vs. IBES Estimate USD -18.8 Million
Express News | Pyxis Oncology Q2 Income From Operations USD -20.032 Million Vs. IBES Estimate USD -20.9 Million
Express News | Pyxis Oncology Q2 Basic EPS USD -0.29
Pyxis Oncology Draws Buy at Stifel on Lead Asset
Pyxis Oncology Initiated at Buy by Stifel
Stifel Initiates Coverage On Pyxis Oncology With Buy Rating, Announces Price Target of $10
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
RBC Capital analyst Leonid Timashev maintains $Pyxis Oncology(PYXS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 49.2%
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Institutional Owners May Ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) Recent US$25m Market Cap Decline as Longer-term Profits Stay in the Green